Cytori Therapeutics Inc (CYTX) : Sabby Management scooped up 1,479,638 additional shares in Cytori Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,966,708 shares of Cytori Therapeutics Inc which is valued at $4,031,751.Cytori Therapeutics Inc makes up approximately 1.33% of Sabby Management’s portfolio.
Other Hedge Funds, Including , D. E. Shaw reduced its stake in CYTX by selling 1,243 shares or 43.26% in the most recent quarter. The Hedge Fund company now holds 1,630 shares of CYTX which is valued at $3,342. Group One Trading sold out all of its stake in CYTX during the most recent quarter. The investment firm sold 1,772 shares of CYTX which is valued $3,633. Argentus Capital Management sold out all of its stake in CYTX during the most recent quarter. The investment firm sold 752 shares of CYTX which is valued $1,542.Feltz Wealth Plan reduced its stake in CYTX by selling 178 shares or 32.96% in the most recent quarter. The Hedge Fund company now holds 362 shares of CYTX which is valued at $681.
Cytori Therapeutics Inc opened for trading at $2.17 and hit $2.27 on the upside on Wednesday, eventually ending the session at $2.19, with a gain of 1.39% or 0.03 points. The heightened volatility saw the trading volume jump to 141,365 shares. Company has a market cap of $45 M.
On the company’s financial health, Cytori Therapeutics Inc reported $-0.43 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.39. The company had revenue of $1.10 million for the quarter, compared to analysts expectations of $3.00 million. The company’s revenue was down -31.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.06 EPS.
Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.